i i cm i i i ii i isi151 - inflibnetshodhganga.inflibnet.ac.in/bitstream/10603/42814/12/12...23....

s ■■■■■alii ■siI I

u S1 ifT m U \W \i

iMfm itm tk ji

H il ll l1:1i ii i1:1i ii ii : ii ii : ii ii ii : ii iISI151ISIl lIII■■Il liuISI■sii iISIISIm

11i i

■l1!■l1

i i■illi!

111111■l1

oCM

Jam

ia

Ham

dard

Chapter 7 Reference

R e f e r e n c e s

1. Abdei-Mottaleb MMA, Neumann D, Lamprecht A. In vitro drug release mechanism from

lipid nanocapsules (LNC). International Journal o f Pharmaceutics 2010;390:208-213.

2. Abdelwahed W, Degobert G, Fessi H. A pilot study o f freeze drying o f

poly(epsiloncaprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation

and process optimization. International Journal o f Pharmaceutics 2006;17:178-188.

3. Abdelwahed W, Degobert G, Fessi IL Investigation o f nanocapsules stabilization by

amorphous excipients during freeze-drying and storage. European Journal o f

Pharmaceutics and Biopharmaceutics 2006;63:87-94.

4. Aditya NP, Patankar S, M adhusudhan B, Murthy RSR, Souto EB. Arthemeter-loaded

lipid nanoparticles produced by modified thin-filrn hydration: Pharmacokinetics,

toxicological and in vivo anti-malarial activity. European Journal o f Pharmaceutical

Sciences 2010;40:448-455.

5. Ahlin P, Kristi J, Kobar S. Optimization of procedure param eters and physical stability o f

solid lipid nanoparticles in dispersion. Acta Pharmaceutica 1998;48:257-67.

6. Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK. Nanostructured lipid carrier

containing CNS acting drug: Formulation, optimization and evaluation. Current

Nanoscience 2011 ;7(6): 1014-1027.

7. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for

effective brain drug delivery. European Journal o f Pharmaceutical Sciences 2010;40:385-

403.

8. Alexis F, Pridgens E, Molnar i.K, Farokhzad OC. Factors Affecting the Clearance and

Biodistribution o f Polymeric Nanoparticles. Molecular Pharmaceutics 2008;5(4):505—

515.

9. Al-Ghananeem AM, Saeed FI, Florence R, Yokel RA, Malkawi AIL Intranasal drug

delivery o f didanosine-loaded chitosan nanoparticles for brain targeting; an attractive

route against infections caused by AIDS viruses. Journal o f Drug Targeting

2010;18(5):381 -388.

10. Ali J, Ali M, Baboota S, Sahani JK,, Ramassamy C, Dao L, Bhavna. Potential o f

nanoparticulate drug delivery systems by intranasal administration. Current

Pharmaceutical Design 2010; 16( 14): 1644-1653.

PhD (Pharmaceutics), Jamia Hamdard 277

Chapter 7 Reference

11. Allison SD, Dong A, Carpenter JF. Counteracting effects o f thiocyanate and sucrose on

chymotrypsinogen secondary structure and aggregation during freezing, drying and

rehydration. Biophysical Journal 1996;71:2022-2032.

12. Allison SD, Molina MDC, Anchordoquy TJ. Stabilization o f lipid/DNA complexes

during the freezing step o f the lyophilization process: the particle isolation hypothesis.

Biochim. Biophysica Acta 2000; 1468:127.

13. Allt G, Lawrenson JG. Pericytes: Cell Biology and Pathology. Cells Tissues Organs

2001;169:1-11.

14. Amidi M, Romeijn SG, V erhoef JC, Junginger HE, Bungener L, Huckriede A,

Crommelin DJA, Jiskoot W. N-Tri methyl chitosan (TMC) nanoparticles loaded with

influenza subunit antigen for intranasal vaccination: Biological properties and

immunogenicity in a mouse model. Vaccine 2007;25:144-153.

15. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation

and characterization o f protein-loaded N-trimethyl chitosan nanoparticles as nasal

delivery system. Journal o f Controlled Release 2006; 111(1 -2): 107 -116.

16. Arborelius L, Owens MJ, Plotsky PM, N em eroff CB. The role o f corticotropin-releasing

factor in depression and anxiety disorders. Journal o f Endocrinology 1999; 160(1): 1-12.

17. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discovery

Today 2002;7(18):967 - 975.

18. Attama AA, Reichl S, Miiller-Goymann CC. Diclofenac sodium delivery to the eye: in

vitro evaluation of novel solid lipid nanoparticleformulation using human cornea

construct. International Journal o f Pharmaceutics 2008;355(l-2):307-13.

19. Aulton ME. “ Pharmaceutics - The science o f dosage form design” Churchill Livingston.,

2002, 494.

20. Aurora .1. Development o f Nasal Delivery Systems: A Review. Drug Delivery

Technology 2002, 1-8.

21. Babbar AK, Singh AIC, Goel HC, Chaulmn US, Sharma RK. Evaluation o f " mTc labeled

Photosan-3, a heamatoporphyrin derivative, as a potential radiopharmaceutical for tum or

scintigraphy. Nuclear Medicine and Biology 2000;27:419-426.

22. Baker IT, Spencer RF. Transneuronal transport o f peroxidase-conjugated wheat germ

agglutinin (W GA-HRP) from the olfactory epithelium to the brain o f the adult rat.

Experimental Brain Research 1986;63(3):461-473.


23. Balin BJ, Broadwell RD, Sal email M, El-Kalliny M. Avenues for entry of peripherally

administered protein to the central nervous system in mouse, rat, and squirrel monkey,

journal of Comparative Neurology 1986;251:260-280.

24. Barakat NS, Omar SA, Ahmed AA. Carbamazepine uptake into rat brain following

intraolfactory transport. Journal o f Pharm acy and Pharmacology 2006;58(l):63-72.

25. Barbu E, M olnar E, Tsibouklis J, Gorecki DC. The potential for nanopaticle based drug

delivery to the brain: overcoming the blood-brain barrier. Expert Opinion on Drug

Delivery 2009;6(6):553-565.

26. Begley DJ. Delivery o f therapeutic agents to the central nervous system: the problems

and the possibilities. Pharmacology and Therapeutics 2004; 104:29-45.

27. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal

insulin improves memory in humans. Psychoneuroendocrinology 20Q4;29:1326-1334.

28. Bentz J, Hill B, Ilium L. Intranasal Administration o f Active Agents to the Central

Nervous System. US Patent Application 2009/0136505 A l .

29. Bernacki J, Dobrowolska A, Nierwihska K, M alecki A. Physiology and pharmacological

role o f the blood-brain barrier. Pharmacological Report 2008;60(5):600-622.

30. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM . Lipid nanoparticles for

transdermal delivery o f flurbiprofen: formulation, in vitro, ex vivo and in vivo studies.

Lipids in Health and Disease 2009;8(6), 1-15.

31. Bickel U, Yoshikawa T, Pardridge WM. Delivery o f peptides and proteins through the

blood-brain barrier. Advanced Drug Delivery Reviews 2001 ;46( 1 -3):247-279.

32. Bickel U. How to Measure Drug Transport across the Blood-Brain Barrier. NeuroRx

2005 ;2( 1): 15-26.

33. Billa N, Yuen KH, Abdul KMA, Omar A. Gamma-scintigraphic study o f the

gastrointestinal transit and in vivo dissolution o f a led release diclofenac sodium

formulation in xanthan gum matrices. International journal o f Pharmaceutics 2000:201;

109-120.

34. Biswas S, Karanjai K. Polymorphic form o f duloxetine hydrochloride. US Patent

Application 2010/0261775 Al.

35. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for

targeted brain drug delivery. Advanced Drug Delivery Reviews 2007;59(6):454-77.

C h ap te r? Reference


Chapter 7 Reference

36. Bond ML, Craparo EF, Giammona G, Cerveilo M, A zzolina A, Diana P, Anna M ,

Cirrincione G. Nanostructured Lipid Carriers-Containing Anticancer Compounds:

Preparation, Characterization, and Cytotoxicity Studies. Drug Delivery 2007; 14(2):61-67.

37. Bondesson E, Asking L, Borgstrom L, Nilsson LE, Trofast E, W o timer P. In vitro and in

vivo aspects of quantifying intrapulmonary deposition o f a dry powder radioaerosol.

International Journal o f Pharmaceutics 2002;232:149-156.

38. Bondi' ML, Giammona G, Craparo EF, Drago F. Nanostructured Lipid Carriers

Containing Riluzole And Phamaceutical formulations containing said particles. US Patent

Application 2010/0247619 AL

39. Bondi ML, Craparo EF, Giammona G, Cerveilo M, Azzolina A, Diana P, M artorana

A, Cirrincione G. Nanostructured lipid carriers-containing anticancer compounds:

preparation, characterization, and cytotoxicity studies. Drug Deli very 2007;14(2):61 -7.

40. Braso A, Princep M, Schmid M, Tabernero A, Perez C, G uglietta A. Developmental

pharmacology: behaviour assay in antipsychotic methods. Clinical Pharma., 2003;25:1-2.

41. Brooking J, Davis SS, Ilium L. Transport o f Nanoparticles across the Rat Nasal Mucosa.

Journal Drag Targeting 2001 ;9(4):267-279.

42. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions

in triglyceride nanoparticles. International Journal o f Pharmaceutics 1996; 129:159-75.

43. Bymaster FP, Beedle EE, Findlay J. Duloxetine (Cymbalta), a dual inhibitor o f serotonin

and norepinephrine reuptake. Bioorganic and Medicinal Chemistry Letter 2003; 13(24):

4477-4480.

44. Carpenter JF, Izutsu KI, Randolph TW . Freezing and drying induced perturbation o f

protein structure and mechanisms o f protein protection by stabilizing additives. In: Rey,

L., May, J.C. (Eds.), Freeze-Drying/Lyophilization o f Pharmaceutical and Biological

Products. 1999. Marcel Dekker, New York.

45. Caspi A, Sugden K, M offitt TE, Taylor A, Craig IW, Harrington FI, Joseph M cClay,

Jonathan Mill, Judy Martin, Antony Braithwaite, Richie Poulton. Influence o f life stress

on depression: moderation by a polymorphism in the 5-HTT gene. Science

2003;301:386-389.

46. Cataldo A, Chen CW, Cohen BM. Methods and compositions for the treatment o f

medical disorders. US Patent Application 2008/0131409 A l.

PhD (Pharmaceutics), Jamia H am dard 280

47. Cegnar M, Kos J, Kristi J. Cystatin incorporated in poly(iactide-co-glycolide)

nanoparticles: development and fundamental studies on preservation o f its activity.

European Journal of Pharmaceutical Sciences 2004;22(5):357-64.

48. Ch’ng HS, Park H, Kelly P, Robinson JR. Bioadhesive polymers as platforms for oral

controlled drug delivery II. Synthesis and evaluation o f some swelling water-insoluble

bioadhesive polymers. Journal Pharmaceutical Sciences 1985;74:339-405.

49. Cheboyina S, Wyandt CM. Wax-based sustained release matrix pellets prepared by a

novel freeze pelletization technique. II. In vitro drug release studies and release

mechanisms. International Journal o f Pharmaceutics 2008;359:167-173.

50. Chein YW, Su KSE, Chang SF. Nasal systemic drug delivery.

Dekker, 1989, 1-77.

51. Chhalotiya UK, Bhatt KK, Shah DA, Baldania SL. Development and validation o f a

stability-indicating RP-HPLC method for duloxetine hydrochloride in its bulk and tablet

dosage form. Scientia Pharmaceutica. 2010;78(4):857-68.

52. Chien, Y.W ., Transnasal systemic medication, Elsevier, Amsterdam, (Y.W.

Chien Ed.), 1985, 42-46.

53. Choi FIG, Jung JPI, Ryu JM, Yoon SJ, Oh YK, Kim CK. Development o f in situ-gelling

and mucoadhesive acetaminophen liquid suppository. International Journal o f

Pharmaceutics 1998; 165:33-44.

54. Choong E, Rudaz S, Kottelat A, Guillarme D, Veuthey JL, Eap CB. Therapeutic drug

monitoring o f seven psychotropic drugs and four metabolites in human plasma by HPLC-

MS. Journal of Pharmaceutical and Biomedical Analysis 2009;50(5):1000-1008.

55. Chung FY, Donovan MD. Nasal pre-systemic metabolism of peptide drugs: Substance P

metabolism in the sheep nasal cavity. International Journal of Pharmaceutics 1996; 128(1-

2):229-237.

56. Conford EM, Hyman S, Swartz BE. The human brain GLUT-1 transporter ultra structural

localization to the blood-brain barrier endothelial cells. Journal o f Cerebral Blood Flow

Metabolism 1994;14:106-112.

57. Corbo DC, Huang YC, Chein YW. Nasal delivery o f progestational

steroids in overiectomized rabbits. I. Progesteron comparison o f pharmacokinetic

with intravenous and oral administration. International Journal o f Pharmaceutics 1998;46:

133-139.

C hap ter? Reference

PhD (Pharmaceutics), Jamia Ham dard 281

Chapter 7 .Reference

58. Cottrell GT, Ferguson AV. Sensory circumventricular organs: central roles in integrated

autonomic regulation. Regular Peptides 2004; 117:11-23.

59. Covinsky KE, Fortinslcy RH, Palmer RM, Kresevic DM, Landefeld CS. Relation between

symptoms o f depression and health status outcomes in acutely ill hospitalized older

persons. Annals o f Internal Medicine 1997; 126(6):417-25.

60. Crone C, Cristensen O. Electrical resistance o f capillary endothelium. Journal o f General

Physiology 1981;77:349-371.

61. Crone C, Olesen SP. Electrical resistance o f brain microvascular endothelium. Brain

Research 1982;241:49-55.

62. Crowe JF1, Crowe LM, Carpenter JF. Preserving dry biomaterials: The w ater replacement

hypothesis. Biopharm International 1993;6:28-37.

63. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in

health and disease. Endocrine Reviews 1998;19:269-301.

64. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test

differentially produced by serotonergic and noradrenergic antidepressants.

Psychopharmacology 1995; 121 ( l):66-72.

65. Dhaneshwar SS, Deshpande P, Patil M, Vadnerkar G, Dhaneshwar SR. Development and

validation o f a FIPTLC method for estimation of Duloxetine Hydrochloride in bulk drug

and in tablet dosage form. Indian Journal of Pharmaceutical Sciences 2008;70(2):233-6.

66. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical Studies To Understand

Nanoparticle Interaction with the Immune System and Its Potential Effects on

Nanoparticle Biodistribution. M olecular Pharmaceutics 2008;5(4):487 - 495.

67. Dodane V, Khan MA, Merwin JR. Effect o f chitosan on epithelial permeability and

structure. International Journal Pharmaceutics, 1999, 21-32.

68. Doktorovova S, Araujo J, Garcia ML, Rakovsky E, Souto EB. Formulating fluticasone

propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids

and Surfaces B: Biointerfaces 2010;75:538-542.

69. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for

the cognitive-emotional features o f mood disorders. Current Opinion in Neurobiology

2001;11:240-249.


70. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, M uller JM. Brain delivery o f

vasoactive intestinal peptide (VIP) following nasal administration to rats. International

Journal o f Pharmaceutics 2003;2551-2):87-97.

7!. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin like growth

factor receptor. Metabolism 1988;37:136-140.

72. Edsman K, Hagers trom I~l. Pharmaceutical applications o f mucoadhesion for the non-oral

routes. Journal o f Pharmacy and Pharmacology 2005;57( 1 ):3-22.

73. Egleton RD, Davis TP. Bioavailability and transport o f peptides and peptide drugs into

the brain. Peptides 1997; 18(9): 1431-1439.

74. Egleton RD, Davis TP. Development o f Neuropeptide Drugs that Cross the Bloocl-Brain

Barrier. NeuroRx 2005;2(l):44-53.

75. Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. Nature

1986;319(6050): 199-203.

76. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers:

function and dysfunction. Seminar in Immunopathology 2009;31 (4):497-511.

77. England RJ, Homer JJ, Knight LC, Ell SR. Nasal pH measurement: a reliable and

repeatable parameter. Clinical Otolaryngology and Allied Sciences 1999;24(l):67-8.

78. Engleman EA, Perry K W, Mayle DA, Wong DT. Simultaneous increases o f extracellular

monoamines in microdialysates from hypothalamus o f conscious rats by duloxetine, a

dual serotonin and norepinephrine uptake inhibitor.

Neuropsychopharmacology 1995; 12(4):287-95.

79. Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery o f valproic acid

via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic

studies using rat electroshock model. International Journal o f Nanomedicine 2 0 1 1;6:

363-371.

80. Farmer A, Eley TC, McGuffin P. Current strategies for investigating the genetic and

environmental risk factors for affective disorders. British Journal o f Psychiatry

2005;186:179-181.

81. Feron VJ, Arts JHE, Kuper CF, Slootweg PJ, Woutersen RA. Health risks associated with

inhaled nasal toxicants. Critical Reviews in Toxicology 2001;31:313-347.

82. Ferreira SLC, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, da Silva EGP,

Portugal LA, dos Reis PS, Souza AS, dos Santos WNL. Box-Behnken design: An

Chapter 7 ' Reference


alternative for the optimization o f analytical methods. Analytica Chimica Acta

2007;597(2): 179-186.

83. Flens MJ, Zaman GJR, van der Valk P, Lzquicrdo MA, Schroeijers AB, Scheffer GL, van

der Groep P, dc Haas M, Meijer CJLM, Scheper R i. Tissue distribution of the multidrug

resistance protein. American Journal o f Pathology 1996;148:1237-1247.

84. Frank HJL, Pardridge WM. A direct in vitro demonstration o f insulin binding to isolated

brain microvessels. Diabetes 1981;30:757-761.

85. Fransen GJ, Salemink PJ, Crommelin DJ. Critical parameters in freezing o f liposomes.

International Journal o f Pharmaceutics 1986;33(l-3):27-35.

86. Freitas C, M ullar RH. Effect o f light and temperature on zeta potential and physical

stability in solid lipid nanoparticles (SL N IM) dispersion. International Journal o f

Pharmaceutics 1998;168:221-229.

87. Frey WH, Liu J, Chen X, Thome RG, Fawcett JR, Ala TA, Rahman YE. Delivery of l25I-

NGF to the brain via the olfactory route. D ing Delivery 1997;4(2):87-92.

88. Frey WH, Liu J, Thome RG, Rahman Y-E. Intranasal delivery of 1251-labeled nerve

growth factor to the brain via the olfactory route. In: Iqbal K, M ortimer JA, Winbiad B,

Wisniewski HM, eds. Research Advances in Alzheimer's Disease and Related Disorders.

New York, NY: John W iley & Sons Ltd; 1995:329-335.

89. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to

treat brain diseases. Neurobiology of Disease 2010;37:48-57.

90. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study o f the potential

o f solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as

carriers for oral calcitonin delivery. European Journal o f Pharmaceutical Sciences

2005;25( I): 133—143.

91. Girardin F. Membrane transporter proteins: a challenge for CNS drug development.

Dialogues in Clinical Neuroscience 2006;8(3):311-321.

92. Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, Frei K. Molecular and

cellular permeability control at the blood-brain barrier. Brain Research Reviews

2001 ;36(2-3):258-264.

93. Goppert, T, Muller R. Protein adsorption patterns on poloxamer and poloxamine-

stabilized solid lipid nanoparticles (SLN). European Journal o f Pharmaceutics and

Biophannaceutics 2005;60:361-372.

Chapter 7 ■ Reference


R e fe ren ce

94. G raff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous

system delivery, journal o f Pharmaceutical Sciences 2005;94:1187-1195.

95. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: A neglected major

illness. Journal of Clinical Psychiatry 1993;54(11):419-24.

96. Gref R, Minamitake Y, Peracchia MX, Trebetskoy VS, Torchilin VP, Langer R.

Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-1603.

97. Gu X, Zhang W, Liu J, Shaw JP, Shen Y, Xu Y, Lu 11, Wu Z. Preparation and

characterization o f a lovastatin-loaded protein-free nanostructured lipid carrierresembling

high-density lipoprotein and evaluation o f its targeting to foam cells. AAPS

PharmSciTech. 2011; 12(4): 1200-8.

98. Han F, Li S, Yin R, Liu H, Xu L. Effect o f surfactants on the formation and

characterization o f a new type o f colloidal drug delivery system: nanostructured lipid

carriers. Colloids and Surfaces A: Physicochemical and Engineering Aspects

2008;315:210-216.

99. Flan R, Fang J, Sung KC, Hu O. M ucoadhesive buccal discs for novel nalbuphine

prodrug controlled delivery: Effect o f formulation variables on drug release and

mucoadhesive performance. International Journal o f Pharmaceutics 1999;177:201-207.

100. Hanson LR, Frey II WH. Intranasal delivery bypasses the blood-brain barrier to target

therapeutic agents to the central nervous system and treat neurodegenerative disease.

BMC Neuroscience 2008;9(Suppl 3):S5.

101. Harashima FJ, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake o f liposomes

through complement activation depending on the size o f liposomes. Pharmaceutical

Research 1994;11:402-406.

102. Hawkins BT, Thomas PD. The Blood-Brain Barrier/Neurovascular Unit in Health and

Disease. Pharmacological Review 2005;57:173-185.

103. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being

outcomes o f patients with depression compared with chronic general medical

illnesses. Archives of General Psychiatry 1995;52(1):11-9.

104. ITeppe K, Fleppe A, Schliebs R. Chitosan-based transport system. US Patent application

2006/0051423 A l.

105. Hermann DM, Bassetti CL. Implications o f ATP-binding cassette transporters for brain

pharmacotherapies. Trends in Pharmacological Sciences 2007;28:128-134.


Chapter 7 Reference

106. Hinrichs WLJ, Mancenido FA, Sanders NN, Braeclcmans K, D e Smedt SC, Denieester J,

Frijlink HW. The choice o f a suitable oligosaccharide to prevent aggregation o f

PEGylated nanoparticles during freeze thawing and freeze drying. International Journal

o f Pharmaceutics 2006;311:237-244.

107. Hirai S, Yashiki T, Matsuzawa T, Mima H. Absorption o f drugs from the nasal mucosa o f

rats. International Journal o f Pharmaceutics 1981 ;7(4):3 17-325.

108. Hirai S, Yashiki T, Mima H. Effect o f surfactants on nasal absorption o f insulin in rats.

International Journal o f Pharmaceutics 1981;9(2): 165-171.

109. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, D avidoff F, Endicott J,

Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, M eyer R, Phillips K,Ross

J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ. The National Depressive and

Manic-Depressive Association consensus statement on the undertreatment o f

depression. Journal o f the American Medical Association 1997;277(4):333—40.

110. Hou D, Xie C, Huang K, Zhu C. The production and characteristics o f solid lipid

nanoparticles (SLNs). Biomaterials 2003;24(10): 1781-1785.

111. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization o f

stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous

system. Colloids and Surfaces B: Biointerfaces 2005;45:167-173.

112. Hu FQ, Jiang SP, Du YZ, Yuan II, Ye YQ, Zeng S. Preparation and characteristics o f

monostearin nanostructured lipid carriers. International Journal o f Pharmaceutics 2006;

314:83-89.

113. Hussain MA, Aungst BJ. Nasal mucosal metabolism of an LH-RH fragment and

inhibition with boroleucine. International Journal o f Pharmaceutics 1994; 105(1):7-10.

114. Hyman SE, Rudorfer MV. Depressive and bipolar mood disorders. In: Dale DC,

Federman DD, eds. Scientific American" Medicine. Volume 3. New York:

Healtheon/WebMD Corp., 2000, Sect. 13, Subsect. II, pp 1.

115. Ilium L. In: Mathiowitz E, Chickering DE, Lehr CM Ed, Bioadhesive formulations for

nasal peptide delivery: Fundamentals, Novel Approaches and Development. Marcel

Dekker. New York 1999; 507-539.

116. Ilium L. Nasal drug delivery: possibilities, problems and solutions. Journal o f Controlled

Release 2003;87:187-198.


Chapter 7 Reference

117. Ilium L. Transport of drugs from the nasal cavity to the central nervous system. European

Journal o f Pharmaceutical Sciences. 2000;! 1(1 ):1-18.

118. Ini S, Abramov M, Liberman A. Pure duloxetine hydrochloride. US Patent Application

2006/0270731 Al.

119. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS. Nasal Drug Delivery

System-Factors Affecting and Applications. Current Drug Therapy, 2007, 2, 27-38.

120. Jahnke S. The theory o f high pressure homogenization. In: M uller RH, Benita S, Bohm

B, editors.Emulsions and nanosuspensions for the formulation o f poorly soluble

thugs. Stuttgart: Medpharm Scientific Publishers; 1998. pp. 177-200.

121. Jain GK, Kandi C, Nande V. Pharmaceutical compositions o f Duloxetine. US Patent

Application 2010/0209498 Al.

122. Jain R, Nabar S, Dandekar P, Hassan P, Aswal V, Tahnon Y, Shet T, Borde L, Ray

K, Patravale V. Formulation and evaluation o f novel micellar nanocarrier for

nasal delivery o f sumatriptan. Nanomedicine 2010;5(4):575-87.

123. Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, Tian X, Liu Y, Zhang Q. In vitro and in

vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.

International Journal o f Biological Macromolecules 2012;50(3):523-529.

124. Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and

brain targeting by the choroid plexus-CSF route. Pharmaceutical Research 2005;22(7):

1011-1037.

125. Jores K, M ehnert W, Mader K. Physicochemical Investigations on Solid Lipid

Nanoparticles and on Oil-Loaded Solid Lipid Nanoparticles: A Nuclear Magnetic

Resonance and Electron Spin Resonance Study. Pharmaceutical Research 2003;20(8):

1274-1283 .

126. Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic

evaluation o f nanostructured lipid carriers for parenteral delivery o f arfemether: Nanoject.


127. Kamila MM, Mondal N, Ghosh LK. A validated UV spectrophotometric method for

determination o f duloxetine hydrochloride. Pharmazie 2007;62(6):414-5.

128. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential o f solid lipid nanoparticles in brain

targeting. Journal Controlled Release 2008;127:97-109.


129. Kazis LE, M iller DR, Clark .1, Skinner K, Lee A, Rogers W, Spiro A, Payne S, Finclce G,

Selim A, Linzer M. Health-related quality o f life in patients served by the Department o f

Veterans Affairs: Results from the Veterans Health Study. Archives o f Internal

Medicine 1998; 158(6):626-32.

130. Keck PE, Elray LM, Clinical pharmacodynamics and pharmacokinetics o f antimanic and

mood stabilizing medications. Journal of Clinical Psychiatry 2002;63:1-11.

131. Kendler KS, Kessler RC, Walters EE, MacLean C, Neale MC, Heath AC, Eaves LJ.

Stressful life events, genetic liability, and onset o f an episode o f major depression in

women. American Journal o f Psychiatry 1995;152:833-842.

132. Khatri K, Goyal AK, Gupta PN, M ishra N, Vyas SP. Plasmid DNA loaded chitosan

nanoparticles for nasal mucosal immunization against hepatitis B. International Journal o f

Pharmaceutics 2008;354(l-2):235-241.

133. Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into

nasal lymphatics in the rat: anatomy, histology, and immunological significance.

Neuropathology and Applied Neurobiology 1993; 19:480-488.

134. Kilts CD. Potential new drug delivery system for antidepressants: an overview. Journal of

Clinical Psychiatry 2003;64:31-33.

135. Kim TW, Chung H, Kwon 1C, Sung PIC, Jeong SY. In vivo gene transfer to the mouse

nasal cavity mucosa using a stable cationic lipid emulsion. Molecules and

Cells 2000; 10(2): 142-147.

136. Kirby LG, Lucki I. Interaction between the forced swimming test and fluoxetine

treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat.

Journal of Pharmacology and Experimental Therapeutics I997;282(2):967-76.

137. K oleSA , Sahoo AK, Avachat MIC. Delayed release compositions of duloxetine. US

20110020439.

138. Koziara JM., Lockman PR, Allen DD, M um per RJ. In situ blood-brain barrier transport o f

nanoparticles. Pharmaceutical Research 2003;20:1772-1778.

139. Kubinyi I i Nonlinear dependence o f biological activity on hydrophobic character: the

bilinear model. Fannaco Science 1979;34(3):248—76.

140. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal

nanoemulsion based brain targeting drug delivery system o f risperidone. International

Journal of Pharmaceutics 2008;358(l-2):285-291.

Chapter 7 '" '̂p Reference


Chapter 7 Reference

141. Kumar M, Misra A, Pathak K. Formulation and characterization o f nanoemulsion o f

olanzapine for intranasal delivery. PDA journal o f Pharmaceutical Science and

Technology 2009a;63(6):501-511.

142. Kumar M, Pathak K, Misra A. Formulation and Characterization o f Nanoemulsion-Based

Drug Delivery System o f Risperidone. Drug Development and Industrial Pharmacy

2009b;35(4):3 87-395.

143. Lang S, Langguth P, Oschmann R, Traving B, Merkle HP. Transport and metabolic

pathway o f thymocartin (TP4) in excised bovine nasal mucosa. Journal o f Pharmacy and

Pharmacology 1996;48:1190-96.

144. Langer RS, Peppas A. Present and future applications o f biomaterials in controlled drug

delivery systems. Biomaterials 1981;2:201-214.

145. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, ICnadler MP.

Metabolism, excretion, and pharmacokinetics o f duloxetine in healthy human subjects.

Drug Metabolism and Disposition 2003;31 (9): 1142—1150.

146. Lee WA, Narog BA, Patapoff TW, Wang YJ. Intranasal bioavailability

o f insulin powder formulation: Effect o f permeation enhancer to protein ratio,

Journal of Pharmaceutical Sciences 1991 ;80(8):725-729.

147. Levinson DF. The genetics o f depression: a review. Biology o f Psychiatry 2006;60:84-

92.

148. Li F, Weng Y, Wang L, He H, Yang J, Tang X. The efficacy and safety o f

bufadienolides-loaded nanostructured lipid carriers. International Journal o f

Pharmaceutics 2010;393:203—211.

149. Li X, Nie S, Kong J, Li N, Ju C, Pan W, A controlled-release ocular delivery system for

ibuprofen based on nanostructured lipid carriers. International Journal o f Pharmaceutics

2008;363:177-182.

150. Li X, Wang D, Zhang J, Pan W. Preparation and pharmacokinetics o f docetaxel based on

nanostructured lipid carriers. Journal o f Pharmacy and Pharmacology 2009; 61(11): 1485—

1492.

151. Lin X, Li X, Zheng L, Yu L, Zhang Q, Liu W. Preparation and characterization o f

monocaprate nanostructured lipid carriers. Colloids and Surfaces A:

Physicochemical and Engineering Aspects 2007;311:106-111.


]52. Liotti M. M ayberg HS. The role o f functional neuro imaging in the neuropsychology o f

depression. Journal o f Clinical and Experimental Neuropsychology 2001;23:121-36.

153. Lippacher A, Muller RH, Mader K. Semisolid SLN dispersions for topical application:

influence o f formulation and production parameters on microstructure. European Journal

o f Pharmaceutics and Biopharmaceutics 2002;53:155-160.

154. Liu CH, Wu CT. Optimization o f nanostructured lipid carriers for lutein delivery.

Colloids and Surfaces A: Physicochemical and Engineering Aspects 2010;3 53:149-156.

155. Liu K, Sun J, Wang Y, He Y, Gao IC, He Z. Preparation and Characterization o f 10-

Hydroxycamptothecin Loaded Nanostructured Lipid Carriers. Drug Development and

Industrial Pharmacy 2008;34:465-471.

156. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding

cassette gene family. NeuroRx. 2005;2(l):86-98.

157. Ma N, Zhang BK, Li HD, Chen BM, Xu P, Wang F, Zhu RH, Feng S, Xiang DX, Zhu

YG. Determination o f duloxetine in human plasma via LC/MS and subsequent

application to a pharmacokinetic study in healthy Chinese volunteers. C'linica Chimica

Acta 2007;380(1 -2): 100-105.

158. M achida M, Sano K, Arakawa M, Hayashi M, Awazu S. Effects of surfactants and

protease inhibitors on nasal absorption o f recombinant human granulocyte colony

stimulating factor (rhG-CSF) in rats. Biological and Pharmaceutical Bulletin

1994;17:1375-1378.

159. Maggio ET. Intranasal administration o f active agents to the central nervous system. US

20110129462A 1.

160. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability

o f clozapine solid lipid nanoparticles after intravenous and intraduodenal administration,

journal of Controlled Release 2005; 107(2) :215—228.

161. Marcus SM, Young EA, Kerber KB, Komstein S, Farabaugh AH, Mitchell J, Wisniewski

SR, Balasubramani GK, Trivedi MFI, Rush AJ. Gender differences in depression:

findings from the STAR*D study. Journal o f Affective Disorders 2005;87:141-50.

162. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery o f solutes to the

central nervous system: fact or fiction? Journal o f Drug Targeting 1998;5(6):415-41.

Chapter 7 a Reference


Chapter 7 Reference

163. Mazure CM, Bruce ML, Maciejewski PK, Jacobs SC. Adverse life events and cognitive-

personality characteristics in the prediction of major depression and antidepressant

response. American Journal of Psychiatry 2000; 157(6):896-903.

164. McCarron PA, Woolfson AD, Keating SM. Response surface m ethodology as a

predictive tool for determining the effects o f preparation conditions on the

physicochemical properties o f poly(isobutylcyanoacrylate) nanoparticles. International

Journal o f Pharmaceutics 1999; 193(l):37-47.

165. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and

applications. Advanced Drug Delivery Reviews 2001 ;47:165-196.

166. Melo LP, Nogueira AM, Lanyas FM, Queiroz ME. Polydim ethylsiloxane/polypyrrole stir

bar sorptive extraction and liquid chromatography (SBSE/LC-UV) analysis of

antidepressants in plasma samples. Analytica Chi mica Acta 2009;633(l):57-64.

167. Mercolini L, Mandrioli R, Cazzolla R, Amore M, Raggi MA. HPLC analysis o f the novel

antidepressant duloxetine in hitman plasma after an original solid-phase extraction

procedure. J Chromatogr B Analyt Technol Biomed Life Sci. 20Q7;S56(l-2):81-87.

168. Miguel-Hidalgo JJ, Rajkowska G. M orphological brain changes in depression: can

antidepressants reverse them? CNS Drugs 2002;16:361-72.

169. M ikos AG, Peppas NA. Bioadhesive analysis o f controlled-release systems. IV. An

experimental method for testing the adhesion o f microparticles with mucosa. Journal o f

Controlled Release 1990;12:31-37.

170. M istrya A, Stolnika S, Ilium L. Nanoparticles for direct nose-to-brain delivery o f drugs.

International Journal of Pharmaceutics 2009;379( 1): 146-157.

171. Miyamoto S, Kollman PA. "What determines the strength of noncovalent association of

ligands to proteins in aqueous solution?". Proc Natl Acad Sci USA 1993;90( 18): 8402-6.

172. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles:

theory to practice. Pharmacology Reviews 2001 ;58:283-318.

173. Molina MC, Armstrong TK, Zhang Y, Patel MM, Lentz YK, Anchordoguy TJ. The

stability of lyophilized lipid/DNA complexes during prolonged storage. Journal

Pharmaceutical Sciences 2004;93:2259.

174. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC,

LDC) for oral drug delivery. Drug Development and Industrial

Pharmacy 2008;34( 12): 1394-405.

PhD (Pharmaceutics), Jamia Ham dard 291

Chapter 7 Reference

175. Muller RH, Range SA, Ravelli V, Thunemann AF, M ehnert W, Souto EB. Cyclosporine-

loacled solid lipid nanoparticles (SLN): Drug—lipid physicochemical interactions and

characterization of drug incorporation. European Journal o f Pharmaceutics and

Biopharmaceutics 2008;68(3):535-544.

176. M uller RH, M ader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug

delivery - a review of the state o f the art. European Journal o f Pharmaceutics and

Biopharmaceutics 2000;50(l):16l-77.

177. MiiHer RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and

nanostructured lipid carriers (NLC) in cosmetic and derraatological preparations.

Advanced Drug Delivery Reviews 2002;54 Suppl 1:8131-55.

178. M uller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral

bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.

International Journal of Pharmaceutics 2006;317(l):82-9.

179. Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett

R, Noel PH, Lawrence V, Lee S, Luther M ,Ramirez G, Richardson WS, Stamm K.

Treatment o f depression-new er pharmacotherapies. Psychopharmacology

Bulletin 1998;34(4):409-795.

180. Murray CGL, Lopez AD. Alternative projections o f mortality and disability by cause

1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.

181. National Advisory Mental Health Council. Health care reform for Americans with severe

mental illnesses. American Journal o f Psychiatry 1993; 150(10): 1447-65.

182. National Institute of Mental Health. Mental health: a report o f the Surgeon General.

Rockville, MD: U.S. Department o f Health and Human Services, Substance Abuse and

Mental Health Services Administration, Center for Mental Health Services, National

Institutes of Health, 1999.

183. Nazzal SM, Sylvester PW. Tocotrienol compositions. US Patent application

2011/0052704 A l.

184. Newman SP, Wilding IR. Gamma scintigraphy: an in vivo technique for assessing the

equivalence o f inhaled products. Internationa] Journal o f Pharmaceutics 1998;170:1-9.

185. Nicholson C, Sykova E. Extracellular space structure revealed by diffusion analysis.

Trends in Neuroscience 1998;21:207-215.


186. NIMH Genetics Workgroup. Genetics and mental disorders. NIH Publication No. 98-

4268. Rockville, MD: National Institute o f Mental Health, 1998.

187. Nnochiri ME, Rhadakrishnan B, Christopher HP, Wes AJ, Ansari AM. Enkephalin

conjugates. US Patent application: 2005/6956051 B l.

188. O ’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and

P-glycoprotein at the blood-brain barrier: clinical significance o f in-vitro and in-vivo

findings. British Journal of Pharmacology 2012; 165: 289-312.

189. Osth K, Paulsson M, Bjork E, Edsman K. Evaluation o f drug release from gels on

pig nasal mucosa in a horizontal Ussing chamber. Journal o f Controlled

Release 2002;83(3):377-88.

190. Panyam J, Chavanpatil MD. Lipid-derived nanoparticles for brain-targeted drug delivery.

US Patent 20100076092.

191. Pardeike A, Hommoss A, Mtiller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and

pharmaceutical dermal products. International Journal o f Pharmaceutics 2009;366:170—

184.

192. Pardeike J, Schwabe K, Muller RH. Influence o f nanostructured lipid carriers (NLC) on

the physical properties of the Cutanova Nanorepair Q10 crcam and the in vivo skin

hydration effect. International Journal o f Pharmaceutics 2010;396:166-173.

193. Pardridge WM. Blood-brain barrier delivery. Drug Discovery Today 2007; 12(1/2): 54-61.

194. Pardridge WM. The blood-brain barrier and neurotherapeutics. NeuroRX. 2005;2(1): 1 -2.

195. Pardridge WM. Vector mediated peptide drug delivery to the brain. Advanced Drug

Delivery Reviews 1995;15:109-146.

196. Patel S, Chavhan S, Soni H, Babbar AK, M athur R, Mishra AK, Sawant K.

Brain targeting o f risperidone-loaded solid lipid nanoparticles by intranasal route. Journal

o f Drug Targeting 2011 ;19(6):468-74.

197. Patel SK, Patel NJ, Patel KM, Patel PU, Patel BH. Estimation

o f Duloxetine Hydrochloride in Pharmaceutical Formulations by RP-HPLC Method.

Indian Journal o f Pharmaceutical Sciences 2008;70(6):825-827.

198. Patel SK, Patel NJ, Prajapati AM, Patel DB, Patel SA. Stability-indicating RP-

HPLC method development and validation for duloxetine hydrochloride in tablets.

Journal o f AOAC International 2010;93( 1): 123-32.

Chapter 7 w Reference


Chapter 7 Reference

199. Patel M, M cCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid

pharmacokinetics o f intravenous temozolomide in non-human primates. Journal o f

Neurooncology 2003;61(3):203-7.

200. Paulus MP, Dulawa SC, Ralph RJ, Geyer MA. Behavioral organization is independent o f

locomotor activity in 129 and C57 mouse strains. Brain Research 1999;835:27-36.

201. Pereira-Lachataignerais J, Pons R, Panizza P, Courbin L, Rouch J, Lopez O. Study and

formation o f vesicle systems with low polydispersity index by ultrasound method.

Chemistry and Physics of Lipids 2006;140( l-2):88-97.

202. Perez AP, Mundina-Weilenmann C, Romero EL, M orilla MJ. Increased brain

radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming

mucoadhesive gels. International Journal o f Nanomedicine. 2012;7:1373-85.

203. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review o f

antidepressant activity. Psychopharmacology 2005; 177(3):245-55.

204. Piles A, Fortuna A, Alves G, Falcao A. Intranasal drug delivery: how, why and what for?

Journal o f Pharmacy and Pharmaceutical Sciences 2009; 12(3):288-311.

205. Pisal SS, Reddy P, Paradkar AR, Mahadik KR, Kadam SS. Nasal

melatonin gels using pluronic PF-127 for chronobiological treatment o f sleep

disorder. Indian journal o f Biotechnology 2004a, 3,369-377.

206. Pisal SS, Shelke V, Mahadik K, Kadam SS. Effect of organogel o f

organogel components on in vitro nasal delivery o f propranolol hydrochloride.

AAPS PharmSci Tech 2004b;5(4):l-9.

207. Porsolt RD, Bertin A, jalfre M. “Behavioral despair” in mice: a primary screening tests

for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.

208. Porsolt RD, Bertin A, Jalfre M. “Behavioral despair” in rats and mice: strain differences

and the effect of imipramine. European Journal Pharmcology 1978; 51: 291-4.

209. Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gaseo MR,

Mauro A. Solid lipid nanoparticles incorporating melatonin as new model for sustained

oral and transdermal delivery systems. Journal o f Nanoscience and Nanotechnology

2007;7(10):3596-601.

210. Pujara CP, Shao Z, Duncan MR, Mitra AK. Effects o f formulation variables on nasal

epithelial cell integrity: Biochemical evaluations. International Journal of Pharmaceutics

1995; 114(2): 197-203.


C hapter 7 Reference

211. Rainer II. M uller, Jana Pardeike, A im an Hommoss. Lipid nanoparticles (SLN, N LC ) in

cosmetic and pharm aceutical dermal products. International Journal o f Pharm aceutics

2009;366:170-184.

212. Raj RVA, Ramesh T, K um ar AP. A validated UV spectrophotometric determ ination o f an

antidepressant drug - Duloxetine hydrochloride from capsule formulations. International

Journal o f Pharm a and Bio Sciences. 2011. 2(1), 716 - 720.

213. Rajkowska G, M iguel-Hidalgo JJ, Wei J, Di 1 ley G, Pittman SD, M eltzer HY, O verholser

JC, Roth BL, S tockm eier CA. M orphom etric evidence for neuronal and glial prefrontal

cell pathology in m ajor depression. Biological Psychiatry 1999;45:1085-98.

214. Rajkowska G. Postm ortem studies in mood disorders indicate altered numbers o f neurons

and glial cells. Biological Psychiatry 2000;48:766-77.

215. Reger M A,W atson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, Belongia DA,

Fishel MA, Plym ate SR, Schellenberg GD, Cherrier MM, Craft S. Effects o f intranasal

insulin on cognition in m em ory-im paired older adults: m odulation by A POE genotype.

N eurobiology o f A ging 2006;27:451-458.

216. Reich G. U ltrasound-induced degradation o f PL A and PLGA during m icrosphere

processing: influence o f formulation variables. European Journal o f Pharmaceutics and

Biopharmaceutics 1998;45(2): 165-71.

217. Reinhard C. and Frey II WH. Delivery o f polynucleotide agents to the central nervous

system. US Patent Application 2006/0216317 A l.

218. Richardson JL, W hetstone J, Fisher AN, W atts P, Farraj NF, Hinchcliffe M, Benedetti,

Ilium L. Gamm a-scintigraphy as a novel m ethod to study the distribution and retention o f

a bioadhesive vaginal delivery system in sheep. Journal o f Controlled Release 1996;42:

133- 142.

2 i 9. Risau W. Differentiation o f endothelium. FASEB Journal 1995;9( 10):926-933.

220. Romeo VD, de MJ, Sileno AP, Pim plaskar HK, Belli CR. Effects o f physicochemical

properties and other factors on system ic nasal drug delivery. A dvanced Drug Delivery

Reviews 1998;29(1~2):89-116.

221. Romeo VD, deM eireles JC, Gries WJ, X ia W J, Sileno AP, Pim plaskar HK, Belli CR.

Optim ization o f systemic nasal drug delivery with pharmaceutical excipients. Advanced

Drug Delivery Reviews 1998;29(1-2):117-133.

PhD (Pharmaceutics), Jam ia H am dard 295

Chapter 7 'Reference

2.22. Romero EL, M orilla MJ, Regts J, Koning GA, Scherphof GL. O n the m echanism o f

hepatic transendothelial passage o f large liposom es. FEBS Letter 1999;448:193-196.

223. Rossa TM , M artineza PM, Rennera JC, Thornea RG, H ansona LR, Frey WH. Intranasal

adm inistration o f interferon beta bypasses the blood-brain barrier to target the central

nervous system and cervical lymph nodes: a non-invasive treatm ent strategy for m ultiple

sclerosis. Journal o f Neuroim m unology 2004; 151:66-77.

224. Rowe RC, Sheskey PI, W eller PJ. Poloxam er. In: H andbook o f Pharm aceutical

Excipients. London: American Pharmaceutical Association, 2003; Pharm aceutical Press.

4 th ed., pp. 447-450.

225. Saari M, Vidgren MT, Koskinen M O, Turjanm aa VM , N iem inen M M. Pulm onary

distribution and clearance o f two beclom ethasone liposome form ulations in healthy

volunteers. International Journal o f Pharm aceutics 1999; 181:1- 9.

226. Saha GB. M ethods o f radiolabeling. In: Physics and Radiobiology o f N uclear M edicine.

Springer-verlag, N ew York, 1993;pp. 100-106.

227. Sakane T, Akizuki M, Yamashita S, Nadai T, H ashida M, Sezaki H. The transport o f a

drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the

lipophilieity o f the drug. Chemical and Pharmaceutical Bulletin 1991;39:2456-2458.

228. Samanidou V, Pantazidou K, Kovatsi L, Njau S, Livanos A. A sim ple HPLC method for

the simultaneous determ ination o f two selective serotonin reuptake inhibitors and two

serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal

fluid. Journal of Separation Sciences 2 0 12;35(7):839-845.

229. Sarafian TA, M ontes C, hm ira T, Qi J, Coppola G, Geschwind D H , Sofroniew MV.

Disruption o f astrocyte STAT3 signaling decreases mitochondrial function and increases

oxidative stress in vitro. PLoS One 2010;5(3):e9532.

230. Satonin DK, M cCulloch JD, Kuo F, Knadler MP. Development and validation o f a liquid

chromatography-tandem mass spectrometric method for the determ ination o f the major

metabolites o f duloxetine in human plasma. Journal o f C hrom atography B: Analytical

Technology Biomedical Life Sciences 2007;852( 1 -2):582-9.

231. Schipper NG, V erhoef JC, M erkus FW. The nasal m ucociliary clearance: relevance to

nasal drug delivery. Pharmaceutical Research 1991;7:807-814.

232. Schmidt MC, Simmen D, Hilbe M, Boderke P, Ditzinger G, Sandow J, Lang S, Rubas W ,

Merkle HP. Validation o f excised bovine nasal mucosa as in vitro m odel to study drug


transport and metabolic pathways in nasal epithelium. Journal o f Pharmaceutical Sciences

2000; 8 9(3): 3 96-407.

233. Scholer N, Hahn H, M uller RH, Liesenfeld O. Effect o f lipid matrix and size o f solid

lipid nanoparticles (SLN) on the viability and cytokine production o f macrophages.


234. Sengamalam R, Ravindran M, Manish G, M eena S. Analytical M ethod Development and

Dissolution Profile o f Duloxetine and M ethylcobalamin By V ierodt’s M ethod. Journal o f

Pharmacy Research 2011,4(2),449-451.

235. Shastri VP, Sussman E, Jayagopal A. Functionalized solid lipid nanoparticles and

methods o f making and using same. US Patent application 2006/0083781 A l.

236. Shen J, Wang Y, Ping Q, Xiao Y, Huang X. M ucoadhesive effect o f thiolated PEG

stearate and its modified NLC for ocular drug delivery. Journal o f Controlled Release

2009;137:217-223.

237. Shipley MT. Transport o f molecules from nose to brain: transneuronal anterograde and

retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish

peroxidase applied to the nasal epithelium. Brain Research Bulletin 1985; 15(2): 129-142.

238. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by

precipitation in O/W emulsions. European Journal o f Pharmaceutics

Biopharmaceutics 1996;43:104-9.

239. Siekmann B, Westesen K. .Melt-homogenized solid lipid nanoparticles stabilized by the

nonionic surfactant tyloxapol- I. Preparation and particle size determination.

Pharmacology Letter 1994;3:194-197.

240. Simon GE, Von Korff M. Suicide mortality among patients treated for depression in an

insured population. American Journal of Epidemiology 1998;47(2): 155—60.

241. Sintov AC, Levy HV, Botner S. Systemic delivery o f insulin via the nasal route using a

new microemulsion system: In vitro and in vivo studies. Journal o f Controlled

Release 2010; 148(2): 168-76.

242. Sippel JM, Giraud GD, Holden WE. Nasal administration o f the nitric oxide synthase

inhibitor L-NAME induces daytime somnolence. Sleep 1999;22(6):786~8.

243. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Ilium L. Evaluation o f the clearance

characteristics o f bioadhesive systems in humans. International Journal of Pharmaceutics

1999;178:55-65.

Chapter 7 ^ Reference


244. Soane RJ, Hinchcliffe M, Davis SS, ilium, L. Clearance characteristics o f chitosan based

formulations in the sheep nasal cavity. International Journal o f Pharmaceutics

2001;217:183-191.

245. Soares JC, Mann JJ. The functional neuroanatomy o f mood disorders. Journal o f

Psychiatric Research 1997;31(4):393-432.

246. Souto EB, Mehnert W, Muller RH. Polymorphic behaviour of Compritol 888 A TO as

bulk lipid and as SLN and NLC. Journal of M icroencapsulation 2006;23(4):417-433.

247. Souto EB, M uller RH. Investigation o f the factors influencing the incorporation o f

clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. Journal of

Microencapsulation 2006;23(4):377-388.

248. Souto EB, M uller RH. SLN and NLC for topical delivery o f ketoconazole. journal o f

Microencapsulation 2005; 22(5):501—510.

249. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development o f a controlled release

formulation based on SLN and NLC for topical clotrimazole delivery. International

Journal of Pharmaceutics 2004;278:71-77.

250. Speiser P. Lipid nanopellets as carrier system for drugs for oral adm inistration, EP

0167825, 1990.

251. Spitzer RL, Kroenke K, Linzer M, Hahn SR, W illiams IB, deGruy FV 3d, Brody D,

Davies M. Health-related quality of life in primary care patients with mental disorders:

Results from the PRIME-MD 1000 study. JAMA. 1995;274(19): 1511 -7.

252. Srinivasulu P, Srinivas KS, Reddy RS, Mukkanti K, Buchireddy R. A validated stability

indicating rapid LC method for duloxetine HC1. Pharmazie 2009;64(l):IO-3.

253. Stevens J, Ploeger BA, van der Graaf PH, D anhof M, de Lange EC. Systemic and

direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous

and intranasal administration. Drug Metabolism and Disposition 2011 ;39(12):2275-82.

254. Stuart S, Cole V. Treatment o f depression following myocardial infarction with

interpersonal psychotherapy. Annals o f Clinical Psychiatry 1996;8(4):203-206.

255. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology o f major depression: review

and meta-analysis. American Journal o f Psychiatry 2000; 157:1552-62.

256. Sung H, Liang TIP, Tu H. Nanoparticles for protein drug delivery. US Patent Application

2009/0155374 Al.

C h ap te r? Reference


Chapter 7 Reference

257. Szmydynger-Chodobska J, Strazielle N, Zink BJ, Ghersi-Egea JF, Chodobski A. The role

o f the choroid plexus in neutrophil invasion after traumatic brain injury. Journal of

Cerebral Blood Flow and Metabolism 2009;29(9): 1503-1516.

258. Teeranachaideelail V, Muller RH, Junyaprasert VB. Encapsulation o f ascorbyl palmitate

in nanostructured lipid carriers (NLC)— Effects o f formulation param eters on

physicochemical stability. International Journal o f Pharmaceutics 2007a;340:198-206.

259. Teeranachaideelail V, Souto EB, Junyaprasert VB, M uller RH. Cetyl palm itate-based

NLC for topical delivery o f Coenzyme Q 10-Developm ent, physicochem ical

characterization and in vitro release studies. European Journal o f Pharmaceutics and

Biopharmaceutics 2007b;67:141—148.

260. Teeranachaideelail V, Souto EB, Muller RH, Junyaprasert VB. Physicochemical

characterization and in vitro release studies o f ascorbyl palmitate-loaded semi-solid

nanostructured lipid carriers (NLC gels). Journal o f M icroencapsulation 2008;25(2):111-

120.

261. Tersaki T, Tsuji A. Drug delivery to the brain utilizing blood-brain barrier transport

systems. Journal Controlled Release 1994;29:163-169.

262. Thorgeirsson TE, Russell CJ, King DS, Shin YK. Direct detennination o f the membrane

affinities o f individual amino acids. Biochemistry. 1996;35(6): 1803-9.

263. Thorne RG, Emory CR, Ala TA, Frey WH. Quantitative analysis o f the olfactory

pathway for drug delivery to the brain. Brain Research 1995;692:278-282.

264. Thorne RG, Frey WH. Delivery o f neurotrophic factors to the central nervous system.

Clinical Pharmacokinetics 2001;40:907-946.

265. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery o f insulin-like growth

factor-1 to the rat brain and spinal cord along olfactory and trigeminal pathways following

intranasal administration. Neuroscience 2004; 127(2):481 -96.

266. Thome RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd. Delivery o f interferon-beta to

the monkey nervous system following intranasal administration.

Neuroscience. 2008;152(3):785-97.

267. Tiwari SB, Amiji MM. A review o f nanocarrier-based CNS delivery systems. Current

Drug Delivery 2006;3(2):219-32.


268. Tsai MJ, Wu PC, Huang YB, Chang JS, Lin CL, Tsai YH, Fang JY. Baicalein loaded in

tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and braintargeting.

International journal o f Pharmaceutics 2012;423(2):461-70.

269. Tsuji A. influx transporters and drug targeting; Application o f peptide and cation

transporters. International Congress Series 2005;1277:75-84.

270. Uchino H, Kanai Y, Do K K, Wempe MF, Chairoungdua A, M orimoto E, A nders MW,

Endou H. Transport o f amino acid-related compounds mediated by L-type amino acid

transporter 1 (LAT1): Insights into the mechanisms o f substrate recognition. M olecular

Pharmacology 2002;61:729-737.

271. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery:

background, applications, trends and future perspectives. Advanced Drug Delivery

Reviews 2005;57:1640-1665.

272. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects o f nasal m ucoadhesive

drug delivery, journal Pharmacy and Pharmacology 2001 ;53( 1 ):3-21.

273. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active

drugs. European Journal of Clinical Pharmacology 2009;65:1063—1070.

274. Van de WH, Gifford E. ADMET in-silico modelling: towards prediction paradise? Nature

Reviews Drug Discovery 2003;2:192-204.

275. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics

o f clozapine solid lipid nanoparticles. Journal o f Controlled Release 2004;24:627-638.

276. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, Alonso MJ. Low m olecular

weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.

European Journal of Pharmaceutics and Biopharmaceutics 2004;57:123-131.

277. Visor GC, Thompson S, Ling T. Nasal absorption o f calcium antagonists

nicardipin in rats and rhesus monkeys. Drug Development and Industrial Pharmacy 1987;

13:1329-1335.

278. Vitoria M, Bentely LB, Juluana M. Marchetti, Richards N. Influence

of lecithin on some physipchemical properties o f poloxamer gels: Rhelogical

microscopic and in vitro permeation studies. International Journal Pharmaceutics

1999;193:49-55.

279. Vladimir P, Testa B, Van De WH. Lipophilieity in Drug Action and Toxicology. New

York: 1996. John Wiley & Sons Ltd. pp. 439. ISBN 978-3-527-29383-4.

Chapter 7 Reference


280. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. Intranasal M ucoadhesive

Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting, Journal o f

Pharmaceutical Sciences 2006;95(3):570 - 580.

281. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting.

Current Drug Delivery 2005;2:165-175.

282. Wadell C, Bjork E, Camber O. Nasal drug delivery - evaluation o f an in vitro model

using porcine nasal mucosa. European Journal Pharmaceutical Sciences 1999;7(3): 197-

206.

283. Wadell C, Bjork E, Camber O. Permeability o f porcine nasal mucosa correlated with

human nasal absorption. European Journal Pharmaceutical Sciences 2003; 18(1 ):47-53.

284. Wang J, Wang H, Zhou X, Tang Z, Liu G, Liu G, Xia Q. Physicochemical

characterization, photo-stability and cytotoxicity o f coenzyme Q10-

loadingnanostructured lipid carrier. journal Nanoscience and

Nanotechnology 2012; 12(3):2136-48.

285. W ang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving

nasal absorption and brain targeting. European Journal o f Pharmaceutics and


286. W ang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, Wang X, Li X, Zhou W. Preparation and

stability study o f norfloxacin-loaded solid lipid nanoparticle suspensions. Colloids and

Surfaces B: Biointerfaces. 2012;98:105-11.

287. Wang D, Gao Y, Yun L. Study on brain targeting o f raltitrexed following intranasal

administration in rats. Cancer Chemotherapy and Pharmacology 2006;57( I):97~104.

288. Wen MM. Olfactory targeting through intranasal delivery o f biopharmaceutical drugs to

the brain - current development. Discovery o f M edicine 2011 ;11(61):497-503.

289. W ermeling DP, Record KA, Archer SM, Rudy AC. A pharmacokinetic and

pharmacodynamic study, in healthy volunteers, o f a rapidly absorbed intranasal

midazolam formulation. Epilepsy Research 2009;83:124-132.

290. Westesen K, Siekmann B. Comparison o f parenteral lipid emulsions and solid lipid

nanoparticles. European Journal o f Pharmaceutics and Biopharmaceutics 1994;40:35S.

291. Williamson DE, Birmaher B, Frank E, Anderson BP, Matty MK, Kupfer DJ. Nature o f

life events and difficulties in depressed adolescents. Journal o f the

American Academy o f Child and Adolescent Psychiatry 1998;37:1049-1057.

Chapter 7 ~ix Reference


292. Wong CF, Yuen KH, Peh KK. An in-vitro method for buccal adhesion studies:

importance of instrument variables. International Journal o f Pharmaceutics 1999;180:47-

57.

293. W ong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR. LY227942, an

inhibitor o f serotonin and norepinephrine uptake; biochemical pharm acology o f a

potential antidepressant drug. Life Sciences 1988;43(24):2049-57.

294. Yang L, Zhang H, Fawcett JP, Mikov M, Tucker IG. Effect o f bile salts on the transport

o f morphine-6-glucuronide in rat brain endothelial cells. Journal o f Pharmaceutical

Sciences 2010, 100(4), 1516-1524.

295. Yang SC, Zhu JB. Preparation and characterization o f camptothecin solid lipid

nanoparticles. Drug Development and Industrial Pharmacy 2002;28(3):265-274.

296. Zhang W, Fang XL. Significant role o f poloxamer in drug transport across blood-brain

barrier. Yao Xue Xue Bao 2008;43(9):890-897.

297. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y. Formulation optimization o f

dihydroartemisinin nanostructured lipid carrier using response surface methodology.

Powder Technology 2010; 197:120-128.

298. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. Nasal absorption enhancement o f

insulin using PEG-grafted chitosan nanoparticles. European Journal o f Pharmaceutics and

Biopharmaceutics 2008;68: 526-534.

299. Zhao X, Zhao Y, Geng L, Li X, W ang X, Liu Z, Wang D, Bi K, Chen X.

Pharmacokinetics and tissue distribution o f docetaxel by liquid chromatography-mass

spectrometry: evaluation o f folate receptor-targeting amphiphilic copolymer

modified nanostructured lipid carrier. Journal o f Chromatography B 2 0 1 1;879(31):3721-

3727.

300. Zolkovic BV, Maclcic JB, Wang L, M cComb JG, McDonough AA. Differential

expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier

and the choroid plexus. Journal o f Biological Chemistry 1993;268:8019-8025.

301. Zur MA, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug

delivery-drug release and release mechanism. European Journal o f Pharmaceutics and


Chapter 7 '0- 'Reference


i i cm i i i ii i isi151 - inflibnetshodhganga.inflibnet.ac.in/bitstream/10603/42814/12/12...23....

Documents